{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Carr RA"],"funding":["AHRQ HHS","NCI NIH HHS"],"pagination":["e538-e544"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8840992"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["277(3)"],"pubmed_abstract":["<h4>Objective</h4>To compare the efficacy and safety of induction FOLFOX followed by PET-directed nCRT, induction CP followed by PET-directed nCRT, and nCRT with CP alone in patients with EAC.<h4>Summary of background data</h4>nCRT with CP is a standard treatment for locally advanced EAC. The results of cancer and leukemia group B 80803 support the use of induction chemotherapy followed by PET-directed chemo-radiation therapy.<h4>Methods</h4>We retrospectively identified all patients with EAC who underwent the treatments above followed by esophagectomy. We assessed incidences of pathologic complete response (pCR), near-pCR (ypN0 with ≥90% response), and surgical complications between treatment groups using Fisher exact test and logistic regression; disease-free survival (DFS) and overall survival (OS) were estimated by the Kaplan-Meier method and evaluated using the log-rank test and extended Cox regression.<h4>Results</h4>In total, 451 patients were included: 309 (69%) received induction chemotherapy before nCRT (FOLFOX, n = 70; CP, n = 239); 142 (31%) received nCRT with CP. Rates of pCR (33% vs. 16%, P = 0.004), near-pCR (57% vs. 33%, P < 0.001), and 2-year DFS (68% vs. 50%, P = 0.01) were higher in the induction FOLFOX group than in the induction CP group. Similarly, the rate of near-pCR (57% vs. 42%, P = 0.04) and 2-year DFS (68% vs. 44%, P < 0.001) were significantly higher in the FOLFOX group than in the no-induction group.<h4>Conclusions</h4>Induction FOLFOX followed by PET-directed nCRT may result in better histopathologic response rates and DFS than either induction CP plus PET-directed nCRT or nCRT with CP alone."],"journal":["Annals of surgery"],"pubmed_title":["Induction FOLFOX and PET-Directed Chemoradiation for Locally Advanced Esophageal Adenocarcinoma."],"pmcid":["PMC8840992"],"funding_grant_id":["P30 CA008748","T32 HS000063","K12 CA184746"],"pubmed_authors":["Janjigian YY","Tan KS","Bott MJ","Bains MS","Park BJ","Molena D","Sihag S","Carr RA","Wu AJ","Jones DR","Rusch VW","Ilson DH","Hsu M","Isbell JM","Maron SB","Harrington CA","Ku GY"],"additional_accession":[]},"is_claimable":false,"name":"Induction FOLFOX and PET-Directed Chemoradiation for Locally Advanced Esophageal Adenocarcinoma.","description":"<h4>Objective</h4>To compare the efficacy and safety of induction FOLFOX followed by PET-directed nCRT, induction CP followed by PET-directed nCRT, and nCRT with CP alone in patients with EAC.<h4>Summary of background data</h4>nCRT with CP is a standard treatment for locally advanced EAC. The results of cancer and leukemia group B 80803 support the use of induction chemotherapy followed by PET-directed chemo-radiation therapy.<h4>Methods</h4>We retrospectively identified all patients with EAC who underwent the treatments above followed by esophagectomy. We assessed incidences of pathologic complete response (pCR), near-pCR (ypN0 with ≥90% response), and surgical complications between treatment groups using Fisher exact test and logistic regression; disease-free survival (DFS) and overall survival (OS) were estimated by the Kaplan-Meier method and evaluated using the log-rank test and extended Cox regression.<h4>Results</h4>In total, 451 patients were included: 309 (69%) received induction chemotherapy before nCRT (FOLFOX, n = 70; CP, n = 239); 142 (31%) received nCRT with CP. Rates of pCR (33% vs. 16%, P = 0.004), near-pCR (57% vs. 33%, P < 0.001), and 2-year DFS (68% vs. 50%, P = 0.01) were higher in the induction FOLFOX group than in the induction CP group. Similarly, the rate of near-pCR (57% vs. 42%, P = 0.04) and 2-year DFS (68% vs. 44%, P < 0.001) were significantly higher in the FOLFOX group than in the no-induction group.<h4>Conclusions</h4>Induction FOLFOX followed by PET-directed nCRT may result in better histopathologic response rates and DFS than either induction CP plus PET-directed nCRT or nCRT with CP alone.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2025-04-18T16:57:13.265Z","creation":"2025-04-07T04:31:02.36Z"},"accession":"S-EPMC8840992","cross_references":{"pubmed":["34387205"],"doi":["10.1097/sla.0000000000005163","10.1097/SLA.0000000000005163"]}}